Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.

@article{Reichle2004PioglitazoneAR,
  title={Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.},
  author={Albrecht Reichle and Klaus J. Bross and Thomas Joesf Vogt and Frauke Bataille and Peter J. Wild and Anna Berand and Stefan W Krause and Reinhard Andreesen},
  journal={Cancer},
  year={2004},
  volume={101 10},
  pages={2247-56}
}
BACKGROUND Combined treatment approaches targeting tumor cells as well as stromal cells may control chemorefractory malignancies. In the current study, the authors sought to test one such combined approach in the treatment of chemorefractory melanoma and soft tissue sarcoma. METHODS A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally… CONTINUE READING
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…